FIELD: medicine.
SUBSTANCE: invention refers to medicine, namely to experimental oncology, endocrinology. Preparation "Tiromel" 20 mcg/100 g in 0.5 ml of physiological saline is administered intraperitoneally to females and males of C57Bl/6 mice once day for 5 days. Then Lewis carcinoma is transplanted subcutaneously in dose of 2 million cells in 0.5 ml of normal saline.
EFFECT: method enables studying the pathogenesis of malignant growth with underlying comorbid pathology, such as hyperthyroidism, which in turn makes it possible to search for adequate effects on the tumour and to study the effect of hyperthyroidism on the development of a malignant tumour.
1 cl, 3 tbl, 2 dwg, 1 ex
Title | Year | Author | Number |
---|---|---|---|
METHOD FOR CREATING AN EXPERIMENTAL MODEL OF TUMOR GROWTH IN CONDITIONS OF HYPOTHYROIDISM | 2021 |
|
RU2779358C1 |
METHOD FOR ENHANCING THE GROWTH OF B16/F10 MELANOMA VERSUS THE GROWTH OF B16/F10 MELANOMA WITH SELF-GRAFTING AND SLOWING THE GROWTH OF LLC (LEWIS CARCINOMA) VERSUS THE GROWTH OF LLC WITH SELF-GRAFTING IN CASE OF MULTIPLE PRIMARY MALIGNANT TUMORS AGAINST THE BACKGROUND OF PRIMARY IMMUNODEFICIENCY | 2021 |
|
RU2759487C1 |
METHOD FOR PREDICTING THE DEVELOPMENT OF TUMOR RECURRENCE IN PAPILLARY THYROID CANCER | 2022 |
|
RU2795086C1 |
METHOD FOR STIMULATING HEMATOGENOUS DISSEMINATION OF CARCINOMA IN EXPERIMENT | 2021 |
|
RU2757676C1 |
METHOD FOR PREDICTING TUMOR INVASION INTO A CAPSULE IN PAPILLARY THYROID CANCER | 2022 |
|
RU2780942C1 |
A METHOD FOR MODELING THE PRIMARY MULTIPLE GROWTH OF MALIGNANT TUMORS WITH THE SUPPRESSION OF ONE TUMOR BY ANOTHER IN THE CONDITIONS OF PRIMARY IMMUNODEFICIENCY | 2021 |
|
RU2750127C1 |
PHOSPHOLIPID COMPOSITION OF DOXORUBICIN FOR TREATING PATIENTS WITH BREAST CANCER | 2019 |
|
RU2714137C1 |
ANTI-TUMOUR AGENT AGAINST LUNG TUMOUR | 2021 |
|
RU2765472C1 |
METHOD FOR PREVENTION OF PULMONARY METASTATIC LESIONS EXPERIMENTALLY | 2013 |
|
RU2546034C1 |
METHOD FOR CREATING ORTHOTOPIC ENDOMETRIAL CANCER MODEL | 2024 |
|
RU2818464C1 |
Authors
Dates
2024-08-16—Published
2023-11-14—Filed